{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:28:07Z","timestamp":1786685287270,"version":"build-2736575974"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03680-7","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:49:34Z","timestamp":1785401374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-6010","authenticated-orcid":false,"given":"Anjay","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Magay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseen","family":"Kady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"1","key":"3680_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou E, Seikrit C, Tang SCW, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9(1):67.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"3680_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000519973","volume":"2","author":"K Scionti","year":"2021","unstructured":"Scionti K, Molyneux K, Selvaskandan H, Barratt J, Cheung CK. New insights into the pathogenesis and treatment strategies in IgA nephropathy. Glomerular Dis. 2021;2(1):15\u201329.","journal-title":"Glomerular Dis"},{"issue":"4S","key":"3680_CR3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","volume":"108","author":"B Rovin","year":"2025","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group, Rovin B, Barratt J, Rovin Brad H., et al. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108(4S):S1\u201371.","journal-title":"Kidney Int"},{"issue":"2","key":"3680_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.36469\/jheor.2021.26129","volume":"8","author":"CS Kwon","year":"2021","unstructured":"Kwon CS, Daniele P, Forsythe A, Ngai C. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy. J Health Econ Outcomes Res. 2021;8(2):36\u201345.","journal-title":"J Health Econ Outcomes Res"},{"issue":"6","key":"3680_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3680_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ki.2015.322","volume":"89","author":"SJ Barbour","year":"2016","unstructured":"Barbour SJ, Espino-Hernandez G, Reich HN, et al. The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int. 2016;89(1):167\u201375.","journal-title":"Kidney Int"},{"issue":"5","key":"3680_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2025.151564","volume":"44","author":"M Ghaddar","year":"2024","unstructured":"Ghaddar M, Canney M, Barbour SJ. IgA nephropathy: epidemiology and disease risk across the world. Semin Nephrol. 2024;44(5):151564.","journal-title":"Semin Nephrol"},{"issue":"11","key":"3680_CR8","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1093\/ndt\/gfaf084","volume":"40","author":"JJ Sim","year":"2025","unstructured":"Sim JJ, Chen Q, Cannizzaro N, et al. CKD progression, kidney failure, and mortality among US patients with IgA nephropathy. Nephrol Dial Transplant. 2025;40(11):2104\u201317.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3680_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"3680_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40620-020-00725-0","volume":"33","author":"R Coppo","year":"2020","unstructured":"Coppo R, Robert T. IgA nephropathy in children and in adults: two separate entities or the same disease? J Nephrol. 2020;33(6):1219\u201329.","journal-title":"J Nephrol"},{"issue":"8","key":"3680_CR11","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00467-024-06361-1","volume":"39","author":"B Su","year":"2024","unstructured":"Su B, Jiang Y, Li Z, et al. Are children with IgA nephropathy different from adult patients? Pediatr Nephrol. 2024;39(8):2403\u201312.","journal-title":"Pediatr Nephrol"},{"key":"3680_CR12","doi-asserted-by":"publisher","first-page":"205435812513225","DOI":"10.1177\/20543581251322571","volume":"12","author":"A Alladin-Karan","year":"2025","unstructured":"Alladin-Karan A, Samuel SM, Wade AW, et al. Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review. Can J Kidney Health. 2025;12:20543581251322571.","journal-title":"Can J Kidney Health"},{"issue":"12","key":"3680_CR13","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.3390\/biomedicines10123027","volume":"10","author":"T Kano","year":"2022","unstructured":"Kano T, Suzuki H, Makita Y, et al. Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy. Biomedicines. 2022;10(12):3027.","journal-title":"Biomedicines"},{"issue":"5","key":"3680_CR14","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1053\/j.ajkd.2015.08.001","volume":"66","author":"AB Fogo","year":"2015","unstructured":"Fogo AB, Lusco MA, Najafian B, Alpers CE. Atlas of renal pathology: IgA nephropathy. Am J Kidney Dis. 2015;66(5):e33\u20134.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3680_CR15","doi-asserted-by":"publisher","first-page":"e0211812","DOI":"10.1371\/journal.pone.0211812","volume":"14","author":"M Kitamura","year":"2019","unstructured":"Kitamura M, Obata Y, Ota Y, et al. Significance of subepithelial deposits in patients diagnosed with IgA nephropathy. PLoS One. 2019;14(2):e0211812.","journal-title":"PLoS One."},{"key":"3680_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1471-2369-12-64","volume":"12","author":"K Onda","year":"2011","unstructured":"Onda K, Ohsawa I, Ohi H, et al. Excretion of complement proteins and its activation marker C5b\u20139 in IgA nephropathy in relation to renal function. BMC Nephrol. 2011;12:64.","journal-title":"BMC Nephrol"},{"key":"3680_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676919","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Xie X, Li J, et al. Complement activation is associated with crescents in IgA nephropathy. Front Immunol. 2021;12:676919.","journal-title":"Front Immunol"},{"issue":"2","key":"3680_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","volume":"40","author":"M Vivarelli","year":"2025","unstructured":"Vivarelli M, Samuel S, Coppo R, et al. IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol. 2025;40(2):533\u201369.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"3680_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","volume":"102","author":"SJ Barbour","year":"2022","unstructured":"Barbour SJ, Coppo R, Zhang H, et al. Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int. 2022;102(1):160\u201372.","journal-title":"Kidney Int"},{"issue":"7","key":"3680_CR20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","volume":"179","author":"SJ Barbour","year":"2019","unstructured":"Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942\u201352.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"3680_CR21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014\u201321.","journal-title":"Kidney Int"},{"issue":"6","key":"3680_CR22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.xkme.2021.06.014","volume":"3","author":"A Amodu","year":"2021","unstructured":"Amodu A, Porteny T, Schmidt IM, Ladin K, Waikar SS. Nephrologists\u2019 attitudes toward native kidney biopsy: a qualitative study. Kidney Medicine. 2021;3(6):1022\u201331.","journal-title":"Kidney Medicine"},{"issue":"10","key":"3680_CR23","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795\u2013803.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3680_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jcm13040947","volume":"13","author":"RS Lim","year":"2024","unstructured":"Lim RS, Yeo SC, Barratt J, Rizk DV. An update on current therapeutic options in IgA nephropathy. J Clin Med. 2024;13(4):947.","journal-title":"J Clin Med"},{"issue":"Suppl 2","key":"3680_CR25","doi-asserted-by":"publisher","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","volume":"16","author":"F Caravaca-Font\u00e1n","year":"2023","unstructured":"Caravaca-Font\u00e1n F, Guti\u00e9rrez E, Sevillano \u00c1M, Praga M. Targeting complement in IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii28-39.","journal-title":"Clin Kidney J"},{"issue":"10","key":"3680_CR26","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1016\/j.ekir.2025.07.005","volume":"10","author":"MA Cunningham","year":"2025","unstructured":"Cunningham MA, Hargett AA, Holloway AK, et al. Proteomic analysis of circulating IgA1-containing immune complexes in patients with IgA nephropathy. Kidney Int Rep. 2025;10(10):3611\u201323.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3680_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3904\/kjim.2020.205","volume":"37","author":"TR Oh","year":"2022","unstructured":"Oh TR, Choi HS, Oh SW, et al. Association between the progression of immunoglobulin A nephropathy and a controlled status of hypertension in the first year after diagnosis. Korean J Intern Med. 2022;37(1):146\u201353.","journal-title":"Korean J Intern Med"},{"issue":"2","key":"3680_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","volume":"84","author":"C Tang","year":"2024","unstructured":"Tang C, Chen P, Si FL, et al. Time-varying proteinuria and progression of IgA nephropathy: a cohort study. Am J Kidney Dis. 2024;84(2):170\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3680_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12882-021-02453-4","volume":"22","author":"S Wang","year":"2021","unstructured":"Wang S, Qin A, Pei G, et al. Cigarette smoking may accelerate the progression of IgA nephropathy. BMC Nephrol. 2021;22(1):239.","journal-title":"BMC Nephrol"},{"key":"3680_CR30","doi-asserted-by":"publisher","first-page":"iv160","DOI":"10.1093\/ndt\/gft286","volume":"28","author":"F Berthoux","year":"2013","unstructured":"Berthoux F, Mariat C, Maillard N. Overweight\/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant. 2013;28:iv160-6.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3680_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000354646","volume":"38","author":"ZY Duan","year":"2013","unstructured":"Duan ZY, Cai GY, Chen YZ, et al. Aging promotes progression of IgA nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2013;38(3):241\u201352.","journal-title":"Am J Nephrol"},{"issue":"9","key":"3680_CR32","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.ekir.2023.06.010","volume":"8","author":"V Tesa\u0159","year":"2023","unstructured":"Tesa\u0159 V, Radhakrishnan J, Charu V, Barratt J. Challenges in IgA nephropathy management: an era of complement inhibition. Kidney Int Rep. 2023;8(9):1730\u201340.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"3680_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00281-021-00884-7","volume":"43","author":"H Zhang","year":"2021","unstructured":"Zhang H, Barratt J. Is IgA nephropathy the same disease in different parts of the world? Semin Immunopathol. 2021;43(5):707\u201315.","journal-title":"Semin Immunopathol"},{"issue":"Suppl 2","key":"3680_CR34","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/ckj\/sfad199","volume":"16","author":"M Lee","year":"2023","unstructured":"Lee M, Suzuki H, Nihei Y, Matsuzaki K, Suzuki Y. Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis. Clin Kidney J. 2023;16(Suppl 2):ii1-8.","journal-title":"Clin Kidney J"},{"issue":"9","key":"3680_CR35","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.ekir.2023.06.016","volume":"8","author":"DJ Caster","year":"2023","unstructured":"Caster DJ, Abner CW, Walker PD, et al. Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep. 2023;8(9):1792\u2013800.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"3680_CR36","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s12325-025-03187-7","volume":"42","author":"RJ Glassock","year":"2025","unstructured":"Glassock RJ. An expert opinion on current and future treatment approaches in IgA nephropathy. Adv Ther. 2025;42(6):2545\u201358.","journal-title":"Adv Ther"},{"key":"3680_CR37","unstructured":"Novartis Pharmaceuticals Corporation. VANRAFIA\u2122 (atrasentan) prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219208s000lbl.pdf. Accessed 8 May 2026."},{"key":"3680_CR38","unstructured":"Novartis Pharmaceuticals Corporation. FABHALTA\u00ae (iptacopan) prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218276s004lbl.pdf. Accessed 8 May 2026."},{"key":"3680_CR39","unstructured":"Otsuka America Pharmaceutical Inc. VOYXACT\u00ae (sibeprenlimab-szsi) prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761434s000lbl.pdf. Accessed 8 May 2026."},{"key":"3680_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.03.003","author":"BH Rovin","year":"2026","unstructured":"Rovin BH, Barratt J, Cook HT, et al. Complement inhibitors and B-cell modifying agents for IgA nephropathy\u2014a Kidney Disease: Improving Global Outcomes (KDIGO) commentary. Kidney Int. 2026. https:\/\/doi.org\/10.1016\/j.kint.2026.03.003.","journal-title":"Kidney Int"},{"issue":"11","key":"3680_CR41","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1016\/j.ekir.2025.09.032","volume":"10","author":"H Selvaskandan","year":"2025","unstructured":"Selvaskandan H, Seethapathy H. Should histology guide treatment decisions in IgA nephropathy? Kidney Int Rep. 2025;10(11):3720\u20133.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3680_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","volume":"20","author":"JR Dunkelberger","year":"2010","unstructured":"Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34\u201350.","journal-title":"Cell Res"},{"key":"3680_CR43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I \u2013 molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.","journal-title":"Front Immunol"},{"key":"3680_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101627","volume":"59","author":"BV Geisbrecht","year":"2022","unstructured":"Geisbrecht BV, Lambris JD, Gros P. Complement component C3: a structural perspective and potential therapeutic implications. Semin Immunol. 2022;59:101627.","journal-title":"Semin Immunol"},{"issue":"7","key":"3680_CR45","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1681\/ASN.2014101000","volume":"26","author":"N Maillard","year":"2015","unstructured":"Maillard N, Wyatt RJ, Julian BA, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26(7):1503\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"3680_CR46","doi-asserted-by":"publisher","first-page":"101341","DOI":"10.1016\/j.smim.2019.101341","volume":"45","author":"M Cserhalmi","year":"2019","unstructured":"Cserhalmi M, Papp A, Brandus B, Uzonyi B, J\u00f3zsi M. Regulation of regulators: role of the complement factor H-related proteins. Semin Immunol. 2019;45:101341.","journal-title":"Semin Immunol"},{"issue":"6","key":"3680_CR47","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","volume":"190","author":"CB Xie","year":"2020","unstructured":"Xie CB, Jane-Wit D, Pober JS. Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets. Am J Pathol. 2020;190(6):1138\u201350.","journal-title":"Am J Pathol"},{"issue":"5875","key":"3680_CR48","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/bmj.3.5875.326","volume":"3","author":"DJ Evans","year":"1973","unstructured":"Evans DJ, Williams DG, Peters DK, et al. Glomerular deposition of properdin in Henoch-Sch\u00f6nlein syndrome and idiopathic focal nephritis. Br Med J. 1973;3(5875):326\u20138.","journal-title":"Br Med J"},{"key":"3680_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.molimm.2019.07.017","volume":"114","author":"A Tortajada","year":"2019","unstructured":"Tortajada A, Gutierrez E, Pickering MC, Praga Terente M, Medjeral-Thomas N. The role of complement in IgA nephropathy. Mol Immunol. 2019;114:123\u201332.","journal-title":"Mol Immunol"},{"issue":"7","key":"3680_CR50","doi-asserted-by":"publisher","first-page":"e40495","DOI":"10.1371\/journal.pone.0040495","volume":"7","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Koo HM, Lim BJ, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One. 2012;7(7):e40495.","journal-title":"PLoS One"},{"issue":"6","key":"3680_CR51","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/his.14318","volume":"78","author":"J Wu","year":"2021","unstructured":"Wu J, Hu Z, Wang Y, et al. Severe glomerular C3 deposition indicates severe renal lesions and a poor prognosis in patients with immunoglobulin A nephropathy. Histopathology. 2021;78(6):882\u201395.","journal-title":"Histopathology"},{"key":"3680_CR52","doi-asserted-by":"publisher","first-page":"107429","DOI":"10.1016\/j.intimp.2021.107429","volume":"93","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Das S, Mukherjee J, et al. Enumerating the role of properdin in the pathogenesis of IgA nephropathy and its possible therapies. Int Immunopharmacol. 2021;93:107429.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"3680_CR53","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1074\/jbc.M508928200","volume":"281","author":"DE Hourcade","year":"2006","unstructured":"Hourcade DE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem. 2006;281(4):2128\u201332.","journal-title":"J Biol Chem."},{"issue":"3","key":"3680_CR54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10238-018-0491-8","volume":"18","author":"E Lukawska","year":"2018","unstructured":"Lukawska E, Polcyn-Adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med. 2018;18(3):297\u2013318.","journal-title":"Clin Exp Med"},{"issue":"2","key":"3680_CR55","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","volume":"3","author":"NR Medjeral-Thomas","year":"2018","unstructured":"Medjeral-Thomas NR, Troldborg A, Constantinou N, et al. Progressive IgA nephropathy is associated with low circulating mannan-binding lectin\u2013associated serine protease-3 (MASP-3) and increased glomerular factor H\u2013related protein-5 (FHR5) deposition. Kidney Int Rep. 2018;3(2):426\u201338.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"3680_CR56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ng.787","volume":"43","author":"AG Gharavi","year":"2011","unstructured":"Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43(4):321\u20137.","journal-title":"Nat Genet"},{"issue":"2","key":"3680_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/ped.13461","volume":"60","author":"Y Kawasaki","year":"2018","unstructured":"Kawasaki Y, Maeda R, Ohara S, Suyama K, Hosoya M. Serum IgA\/C3 and glomerular C3 staining predict severity of IgA nephropathy. Pediatr Int. 2018;60(2):162\u20137.","journal-title":"Pediatr Int"},{"issue":"7","key":"3680_CR58","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00467-014-3024-z","volume":"30","author":"M Mizerska-Wasiak","year":"2015","unstructured":"Mizerska-Wasiak M, Ma\u0142dyk J, Rybi-Szumi\u0144ska A, et al. Relationship between serum IgA\/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy. Pediatr Nephrol. 2015;30(7):1113\u201320.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"3680_CR59","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","volume":"92","author":"NR Medjeral-Thomas","year":"2017","unstructured":"Medjeral-Thomas NR, Lomax-Browne HJ, Beckwith H, et al. Circulating complement factor H\u2013related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int. 2017;92(4):942\u201352.","journal-title":"Kidney Int"},{"key":"3680_CR60","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000967","author":"DV Rizk","year":"2025","unstructured":"Rizk DV, Dixon BP, Chan M, Cook HT, Frazer-Abel A, Tang SCW. Biomarkers in the management of complement-mediated kidney diseases in the era of complement therapeutics. Clin J Am Soc Nephrol. 2025. https:\/\/doi.org\/10.2215\/CJN.0000000967.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3680_CR61","unstructured":"Calliditas Therapeutics AB. TARPEYO\u00ae (budesonide) delayed release capsules prescribing information. 2024. https:\/\/www.tarpeyo.com\/prescribinginformation.pdf. Accessed 8 May 2026."},{"key":"3680_CR62","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.2147\/DDDT.S383138","volume":"18","author":"J Barratt","year":"2024","unstructured":"Barratt J, Kristensen J, Pedersen C, Jerling M. Insights on Nefecon\u00ae, a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy. Drug Des Devel Ther. 2024;18:3415\u201328.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"3680_CR63","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","volume":"188","author":"M Hahne","year":"1998","unstructured":"Hahne M, Kataoka T, Schr\u00f6ter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188(6):1185\u201390.","journal-title":"J Exp Med"},{"issue":"7","key":"3680_CR64","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","volume":"394","author":"V Perkovic","year":"2026","unstructured":"Perkovic V, Trimarchi H, Tesar V, et al. Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial. N Engl J Med. 2026;394(7):635\u201346.","journal-title":"N Engl J Med"},{"key":"3680_CR65","unstructured":"Travere Therapeutics Inc. FILSPARITM (sparsentan) prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216403s000lbl.pdf. Accessed 8 May 2026."},{"issue":"11","key":"3680_CR66","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.ekir.2023.07.023","volume":"8","author":"DE Kohan","year":"2023","unstructured":"Kohan DE, Barratt J, Heerspink HJL, et al. Targeting the endothelin A receptor in IgA nephropathy. Kidney Int Rep. 2023;8(11):2198\u2013210.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"3680_CR67","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1042\/CS20240249","volume":"138","author":"DE Kohan","year":"2024","unstructured":"Kohan DE, Bedard PW, Jenkinson C, Hendry B, Komers R. Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease. Clin Sci (Lond). 2024;138(11):645\u201362.","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"3680_CR68","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in patients with IgA nephropathy. N Engl J Med. 2025;392(6):544\u201354.","journal-title":"N Engl J Med"},{"issue":"5","key":"3680_CR69","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.34067\/KID.0000001000","volume":"7","author":"JJ Kuo","year":"2025","unstructured":"Kuo JJ, Wu J, Gunawan MG, et al. Effects of atrasentan on kidney gene transcription, mesangial cell proliferation, and proteinuria in immunoglobulin A nephropathy. Kidney360. 2026;7(5):1003\u201316.","journal-title":"Kidney360"},{"issue":"8","key":"3680_CR70","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.2337\/db15-1413","volume":"65","author":"MGS Boels","year":"2016","unstructured":"Boels MGS, Avramut MC, Koudijs A, et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes. 2016;65(8):2429\u201339.","journal-title":"Diabetes"},{"issue":"6","key":"3680_CR71","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392(6):531\u201343.","journal-title":"N Engl J Med"},{"issue":"7","key":"3680_CR72","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/10408363.2021.1907297","volume":"58","author":"MAV Willrich","year":"2021","unstructured":"Willrich MAV, Braun KMP, Moyer AM, Jeffrey DH, Frazer-Abel A. Complement testing in the clinical laboratory. Crit Rev Clin Lab Sci. 2021;58(7):447\u201378.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"3","key":"3680_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","volume":"106","author":"M Vivarelli","year":"2024","unstructured":"Vivarelli M, Barratt J, Beck LH Jr, et al. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2024;106(3):369\u201391.","journal-title":"Kidney Int"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03680-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03680-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03680-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:01:32Z","timestamp":1786683692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03680-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":73,"alternative-id":["3680"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03680-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anjay Rastogi has received advisory board and speakers\u2019 bureau fees from AstraZeneca and Relypsa, has received research grants from AstraZeneca and Bayer, and has received consulting fees from Bayer. Yelena Magay has received speaker\u2019s bureau fees from Natera. Yaseen Kady has no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}